C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273)
11/2002
11/06/2002	EP1254162A2 Kahalalide f and related compounds
11/06/2002	EP1254161A2 Aerothricin analogs, their preparation and use
11/06/2002	EP1254160A1 Par4 peptides and polypeptides
11/06/2002	EP1091966B1 N-terminal site selective inhibitors of human angiotensin conversion enzyme (ace)
11/06/2002	EP0726758B1 Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
11/06/2002	EP0635025B1 Process for preparing modified proteins
11/06/2002	CN1377888A Method for getting high purity microcystoxin
11/06/2002	CN1377887A Polypeptide for inhibiting growth and migration of blood vessel endothelial cell and endothelial stem cell and its preparing method and use
11/06/2002	CN1093881C Process for preparation of immunogens or diagnostic reagents, and method for obtaining immunogens or diagnostic reagents
11/05/2002	US6476191 Volatilizable solid phase supports for compound synthesis
11/05/2002	US6476190 Process for preparing modified proteins
11/05/2002	US6476189 Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient
11/05/2002	US6476187 Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
11/05/2002	US6476186 Process for preparing octreotide and derivatives thereof
11/05/2002	US6475988 Methods to increase white blood cell survival after chemotherapy
11/05/2002	US6475806 Anchor libraries and identification of peptide binding sequences
11/05/2002	US6475753 94 Human Secreted Proteins
11/05/2002	US6475507 Sustained release compositions and the process for their preparation
11/05/2002	CA2109322C Bombesin analogs
11/05/2002	CA1341396C Cyclosporin crystal form, processes for its production pharmaceutical compositions containing it and its use
11/02/2002	CA2346154A1 Gastrin receptor-avid peptide conjugates
10/2002
10/31/2002	WO2002086070A2 Binding molecules for fc-region polypeptides
10/31/2002	WO2002085941A2 Modified interferon alpha with reduced immunogenicity
10/31/2002	WO2002085928A2 Modified cyclosporine which can be used as a pro-drug and use thereof
10/31/2002	WO2002085927A1 Novel anti-inflammatory peptides
10/31/2002	WO2002085401A1 Retrocyclins: antiviral and antimicrobial peptides
10/31/2002	WO2002085307A2 Glycopeptide antibiotics
10/31/2002	WO2002068585A3 Tip39 polypeptides
10/31/2002	WO2002062961A9 Peptide scaffold encapsulation of tissue cells and uses thereof
10/31/2002	WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002	WO2002028886A3 Caloxins their isolation and use
10/31/2002	WO2001057072A3 Pharmacologically active antiviral peptides and methods of their use
10/31/2002	WO2001053342A9 Chimeric prostate-homing peptides with pro-apoptotic activity
10/31/2002	WO2001053331A9 Peptidomimetic modulators of cell adhesion
10/31/2002	WO2001052746A9 Versatile hydrophilic dyes
10/31/2002	US20020161176 Providing solution comprising an echinocandin compound, an aldehyde impurity and solvent; concentrating by nanofiltration to form concentrate; adding derivatizing agent to react with aldehyde; adjusting pH, adding acid or metal salt; cooling
10/31/2002	US20020160962 Non-structural protein 3 (NS3), part of a hepatitis C virus protease necessary for polypeptide processing and viral replication; alpha-ketoamide compounds of given formula
10/31/2002	US20020160959 Therapeutic compounds for ovarian cancer
10/31/2002	US20020160942 Echinocandin/carbohydrate complexes
10/31/2002	US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002	US20020160432 Quantitative analysis; diagnosis of infections
10/31/2002	US20020160383 Use of nucleic acid analogues in diagnostics and analytical procedures
10/31/2002	US20020160019 Providing peptide that bears a DR motif corresponding to a Class II HLA molecule, testing peptide for binding affinity to a Class II HLA DR molecule, whereupon an IC50 binding affinity is determined
10/31/2002	US20020160013 Used in diagnosis and therapy of diseases that involve inadequate or inappropriate receptor response as well as in the screening of drug candidates that affect surface expression of receptors
10/31/2002	US20020160009 For treatment of disseminated candidiasis due to infection by C. albicans; composition includes phosphomannan of C. albicans
10/31/2002	CA2444680A1 Binding molecules for fc-region polypeptides
10/31/2002	CA2444673A1 Glycopeptide antibiotics
10/31/2002	CA2444626A1 Retrocyclins: antiviral and antimicrobial peptides
10/31/2002	CA2439690A1 Modified interferon alpha with reduced immunogenicity
10/30/2002	EP1252179A2 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
10/30/2002	EP1252178A1 Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
10/30/2002	EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002	EP1251865A1 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
10/30/2002	EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
10/30/2002	EP0907887A4 Engineering affinity ligands for macromolecules
10/29/2002	US6472537 Polyamides for binding in the minor groove of double stranded DNA
10/29/2002	US6472522 Purification of oligomers using dual-end selection
10/29/2002	US6472505 Treatment of physiological conditions capable of being modulated by agonist or antagonist activity on parathyroid hormone receptors
10/29/2002	US6472368 Compounds and methods for modulating adhesion molecule function
10/29/2002	US6472146 Methods for identification on internalizing ligands and identification of known and putative ligands
10/29/2002	CA2060034C Tumour growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same
10/28/2002	EP0831872A4 Polypeptide compounds that form beta sheets
10/24/2002	WO2002083928A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/24/2002	WO2002083917A2 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
10/24/2002	WO2002083916A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	WO2002083858A2 Methods to inhibit viral replication
10/24/2002	WO2002083738A1 Cyclic single strand trispecific antibody
10/24/2002	WO2002083729A2 Polypeptides derived from amyloid precursor peptide (app) and their uses
10/24/2002	WO2002083718A1 Carbohydrate-specific peptides which have a strong affinity and preparation method thereof
10/24/2002	WO2002083713A2 Echinocandin process
10/24/2002	WO2002083161A1 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock
10/24/2002	WO2002083065A2 Peptide antiangiogenic drugs
10/24/2002	WO2002045524A3 Prolyl endoprotease from aspergillus niger
10/24/2002	WO2001074848A3 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use
10/24/2002	WO2001068676A3 Lhrh-antagonists, production and use thereof as medicament
10/24/2002	US20020156117 Receptor-avid exogenous optical contrast and therapeutic agents
10/24/2002	US20020156017 Antimicrobial peptides and methods of use thereof
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155607 Multifunctional molecular complexes for gene transfer to cells
10/24/2002	US20020155588 Very large scale immobilized polymer synthesis
10/24/2002	US20020155471 Compounds for therapy and diagnosis and methods for using same
10/24/2002	US20020155106 Used for multiple screenings of the same surface-immobilized library for a number of different ligands
10/24/2002	DE10117281A1 Peptid zur Diagnose und Therapie der Alzheimer-Demenz Peptide for diagnosis and therapy of Alzheimer's disease
10/24/2002	DE10116042A1 Exotoxin-Ligand Exotoxin-ligand
10/24/2002	CA2444530A1 Polypeptides, derivatives and uses thereof
10/24/2002	CA2444047A1 Methods to inhibit viral replication
10/24/2002	CA2443733A1 Peptide antiangiogenic drugs
10/24/2002	CA2443726A1 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock
10/24/2002	CA2443705A1 Cyclic single strand trispecific antibody
10/24/2002	CA2443141A1 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/23/2002	EP1251137A2 Use of insulin-like growth factor agonist peptides
10/23/2002	EP1250600A2 Diagnosis of tauopathies determining tau/phospho-tau ratio
10/23/2002	EP1250358A1 Therapeutic peptides
10/23/2002	EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity
10/23/2002	EP1250351A2 Methods to identify ctl epitopes of hiv
10/23/2002	EP1250333A1 Dendrimer precursor dyes for imaging
10/23/2002	EP1250145A1 C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
10/23/2002	EP1250095A1 Versatile hydrophilic dyes
10/23/2002	EP1250093A1 Novel indocyanine dyes
10/23/2002	EP1250092A1 Novel dyes

1 ... 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 ... 423